Rochlani, Y., Pothineni, NV, Kovelamudi, S. & Mehta, JL Metabolic syndrome: pathophysiology, management and modulation by natural compounds. The. Adv. Cardiovascular. Say. 11215-225 (2017).
Justice, CA et al. Predictive accuracy of the Veterans Aging Cohort Study Index for HIV infection mortality. JAIDS J. Acquire. Immune Challenge. syndr. 62149-163 (2013).
Scuteri, A. et al. Metabolic syndrome across Europe: different groups of risk factors. EUR. J. Prev. Cardole. 22486–491 (2015).
Alberti, KG & Zimmet, PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus interim report of a WHO consultation. Diabetes. Med. 15539-553 (1998).
Einhorn, D. et al. American College of Endocrinology position statement on insulin resistance syndrome. Endocr. Practice. 9237–252 (2003).
Alberti, KGMM, Zimmet, P. & Shaw, J. Metabolic syndrome – a new global definition. A consensus statement from the International Diabetes Federation. Diabetes. Med. 23469-480 (2006).
Grundy, SM et al. Diagnosis and management of metabolic syndrome: a scientific statement from the American Heart Association/National Heart, Lung, and Blood Institute. Traffic 1122735–2752 (2005).
Alberti, KGMM et al. Harmonizing metabolic syndrome: a joint interim statement from the International Diabetes Federation Epidemiology and Prevention Working Group; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International. Traffic 1201640–1645 (2009).
Ference, BA, Kastelein, JJP & Catapano, AL Lipids and Lipoproteins in 2020. JAMA J.Am. Med. Assoc. 324595–596 (2020).
Google Scholar
Simmons, RK et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO expert consultation. Diabetology 53600–605 (2010).
Tauler, P. et al. Prevalence of premorbid metabolic syndrome in Spanish adult workers using the IDF and ATPIII diagnostic criteria: Relationship with cardiovascular risk factors. PLoS One 9e89281 (2014).
Observatorio Español de las Drogas las Adicciones Delegación del Gobierno para el Plan Nacional sobre Drogas. Monograph. Alcohol 2021: consumption and consequences. (2021). https://pnsd.sanidad.gob.es/profesionales/publicaciones/catalogo/catalogoPNSD/publicaciones/pdf/2021_Monografia_Alcohol_consumos_y_consecuencias.pdf
Vancampfort, D. et al. The prevalence of metabolic syndrome in alcohol use disorders: a systematic review and meta-analysis. Alcohol Alcohol. 51515–521 (2016).
Jarvis, C.M. et al. Cardiovascular risk factors and metabolic syndrome in men and women dependent on alcohol and nicotine. J. Cardiovascular. Nurses. 22429–435 (2007).
Hernandez-Rubio, A. et al. Association of hyperuricemia and gamma glutamyl transferase as a marker of metabolic risk in alcohol use disorders. Science. representing ten20060 (2020).
Abdul-Rahman, AK, Card, TR, Grainge, MJ & Fleming, KM All-cause and cause-specific mortality rates of patients treated for alcohol use disorders: a meta-analysis. noun A bus. 39509–517 (2018).
Kim, S.J. & Kim, D.-J. Alcoholism and diabetes mellitus. Diabetes Metab. J 36108–115 (2012).
Levey, AS et al. A new equation for estimating glomerular filtration rate. Ann. Internal. Med. 150604–612 (2009).
Ryan, MC, Fenster Farin, HM, Abbasi, F. & Reaven, GM Comparison of waist circumference versus body mass index in the diagnosis of metabolic syndrome and identification of apparently healthy subjects at risk increased cardiovascular disease. A m. J. Cardiol. 10240–46 (2008).
Jayedi, A., Soltani, S., Zargar, MS, Khan, TA & Shab-Bidar, S. Central adiposity and risk of all-cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ 370m3324 (2020).
Guallar-Castillon, P. et al. Extent and management of the metabolic syndrome in Spain in 2008-2010: the ENRICA study. Rev. Española Cardiol. (English ed.) 67367–373 (2014).
Google Scholar
Kassi, E., Pervanidou, P., Kaltsas, G. & Chrousos, G. Metabolic syndrome: definitions and controversies. BMC Med. 948 (2011).
Zhang, X. & Lerman, LO Metabolic syndrome and chronic kidney disease. Transl. Res. 18314–25 (2017).
Garofalo, C. et al. A systematic review and meta-analysis suggest that obesity predicts the onset of chronic kidney disease in the general population. Kidney Int. 911224-1235 (2017).
Yamagata, K. et al. Effect of behavior modification on outcome in early-to-moderate chronic kidney disease: a cluster-randomised trial. PLoS One 11e0151422 (2016).
Câmara, NOS, Iseki, K., Kramer, H., Liu, ZH and Sharma, K. Kidney disease and obesity: epidemiology, mechanisms and treatment. Nat. Rev. Nephrol. 13181-190 (2017).
Park, S. et al. Reduced risk of chronic kidney disease after recovery from metabolic syndrome: a national population-based study. Kidney Res. Clin. Practice. 39180-191 (2020).
Choi, J.I. et al. The association between obesity phenotypes and early decline in renal function in adults without hypertension, dyslipidemia and diabetes. Korean J. Fam. Med. 40176–181 (2019).
Wu, Z. et al. Metabolic syndrome is associated with a rapid decrease in estimated glomerular filtration rate in a Chinese communal population. Diabetes Metab. syndr. Obese. Thermal targets. 122085-2093 (2019).
Kawamoto, R., Akase, T., Ninomiya, D., Kumagi, T. & Kikuchi, A. Metabolic syndrome is a predictor of decreased kidney function in middle-aged and elderly Japanese living in the community . Int. Urol. Nephrol. 512285-2294 (2019).
Lee, DS et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease and mortality risk: The Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 27127–133 (2007).
Voruganti, VS et al. Genetic influence on variation in serum uric acid among American Indians: the strong heart family study. Hmm. Broom. 126667–676 (2009).
Kunutsor, SK, Apekey, TA & Seddoh, D. Gamma glutamyltransferase and risk of metabolic syndrome: systematic review and dose-response meta-analysis. Int. J. Clin. Practice. 69136–144 (2015).
Bonomini, F., Rodella, LF & Rezzani, R. Metabolic syndrome, aging and the involvement of oxidative stress. Aging Dis. 6109-120 (2015).
Bo, S. et al. Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: a possible implication for oxidative stress. World J. Gastroenterol. 117109–7117 (2005).
Koenig, G. & Seneff, S. Gamma-Glutamyltransferase: a predictive biomarker of cellular antioxidant insufficiency and disease risk. Say. Mark. 2015818570 (2015).
Google Scholar
Lai, X. et al. Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji cohort. Int. J. Cardiol. 224299–304 (2016).
Yadav, D. et al. Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. Atherosclerosis 241271–277 (2015).
Lil. et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? : A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 15122 (2014).
Razzouk, L. & Muntner, P. Ethnic, sex, and age differences in patients with metabolic syndrome. Running. Hypertens. representing 11127-132 (2009).
Jiang, B. et al. Age and sex distribution of metabolic syndrome components in eastern China: role of hypertriglyceridemia in the SPECT-China study. Lipids Health Dis. 1792 (2018).
Yamaki, N. et al. Telomere shortening in alcohol dependence: roles of alcohol and acetaldehyde. J. Psychiatrist. Res. 10927–32 (2019).
Wu, HF et al. Age, gender, and socioeconomic gradients in metabolic syndrome: biomarker evidence from a large sample in Taiwan, 2005-2013. Ann. Epidemiol. 27315-322.e2 (2017).
